William Blair Has Pessimistic Outlook of ELAN Q2 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Analysts at William Blair dropped their Q2 2025 earnings estimates for Elanco Animal Health in a report issued on Tuesday, February 25th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.22 per share for the quarter, down from their previous forecast of $0.27. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health's Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.91 EPS.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business earned $0.08 EPS. The company's revenue for the quarter was down 1.4% on a year-over-year basis.

Several other equities research analysts also recently weighed in on ELAN. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Morgan Stanley decreased their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday. Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday. Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Finally, Leerink Partners initiated coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Hold" and a consensus price target of $15.83.

Elanco Animal Health Trading Up 2.4 %

Shares of NYSE:ELAN traded up $0.27 during mid-day trading on Thursday, hitting $11.19. The company had a trading volume of 6,902,175 shares, compared to its average volume of 4,959,782. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a one year low of $10.20 and a one year high of $18.80. The firm has a fifty day moving average price of $11.72 and a 200 day moving average price of $13.05. The company has a market capitalization of $5.53 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the company. FMR LLC grew its position in Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 6.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock worth $216,774,000 after purchasing an additional 1,074,274 shares during the last quarter. Shapiro Capital Management LLC increased its position in shares of Elanco Animal Health by 7.5% during the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock valued at $149,640,000 after purchasing an additional 862,900 shares during the last quarter. Magnetar Financial LLC raised its stake in shares of Elanco Animal Health by 13.7% during the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after purchasing an additional 1,454,082 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after buying an additional 4,361,799 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.